Sanofi Consumer Healthcare India Ltd
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare Nifty Microcap 250 Nifty Total Market BSE 1000
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|
| Advertisement & Sales Promotion as % of Revenue % ・Standalone data |
|
||
| Brand Market Share (IQVIA MAT) % ・Standalone data |
|||
| Field Force (Medical Representatives) count ・Standalone data |
|||
| Number of Dealers/Distributors count ・Standalone data |
|||
| Cities Served count ・Standalone data |
|||
| HCP Digital Engagement Reach count ・Standalone data |
|||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Intimation for Board Meeting Intimation For Consideration And Approval Of Unaudited Financial Results For The Quarter And Half Year Ended 30Th June 2026.
2d - Board meeting on 28 July 2026 to approve Q1 and half-year FY2026 unaudited results; trading window closed till 30 July.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Jul - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 3oth June 2026 is enclosed.
-
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
29 Jun - Shareholders approved PwC as statutory auditor from 25 May 2026 through 8th AGM in 2031.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 29 Jun
- Shareholder Meeting / Postal Ballot-Outcome of AGM 26 Jun
Annual reports
Concalls
-
Mar 2026Transcript PPT
Business Overview:[1][2]
SCHIL was formed following its demerger from Sanofi India Limited, to establish a standalone Consumer Healthcare (CHC) business. It operates in the Consumer Healthcare (CHC) sector, providing self-care solutions across various health categories including allergy relief, pain management, and wellness